NASDAQ:BOLD Audentes Therapeutics (BOLD) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.32▼$3.7250-Day Range$59.97▼$59.9752-Week Range$22.00▼$60.00Volume22,681 shsAverage Volume75,127 shsMarket Capitalization$80.99 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends Get Audentes Therapeutics alerts: Email Address Audentes Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside531.9% Upside$23.00 Price TargetShort InterestBearish5.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.92) to ($3.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.48 out of 5 starsMedical Sector883rd out of 924 stocksPharmaceutical Preparations Industry411th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAudentes Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAudentes Therapeutics has received no research coverage in the past 90 days.Read more about Audentes Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.29% of the float of Audentes Therapeutics has been sold short.Short Interest Ratio / Days to CoverAudentes Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Audentes Therapeutics has recently increased by 1.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAudentes Therapeutics does not currently pay a dividend.Dividend GrowthAudentes Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BOLD. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Audentes Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Audentes Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Audentes Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Audentes Therapeutics is held by insiders.Read more about Audentes Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Audentes Therapeutics are expected to decrease in the coming year, from ($3.92) to ($3.98) per share.Read more about Audentes Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Audentes Therapeutics Stock (NASDAQ:BOLD)Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. BOLD Stock News HeadlinesAugust 21 at 8:45 PM | 247wallst.comBoundless Bio Inc. Common StockAugust 12, 2024 | globenewswire.comBoundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial ResultsAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 5, 2024 | businesswire.comBoundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 13, 2024 | businesswire.comBoundless Bio Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 6, 2024 | businesswire.comBoundless Bio to Present at the Citizens JMP Life Sciences Conference 2024April 30, 2024 | finance.yahoo.comMalignant Ascites Market to Observe Growth at a CAGR of 1.2% by 2034 | DelveInsightApril 26, 2024 | seekingalpha.comBOLD Boundless Bio, Inc.August 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.April 11, 2024 | bbc.co.ukBold GirlsApril 11, 2024 | businesswire.comBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsApril 11, 2024 | morningstar.comBoundless Bio Inc BOLDApril 8, 2024 | businesswire.comBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024March 27, 2024 | businesswire.comBoundless Bio Announces Pricing of Initial Public OfferingNovember 25, 2023 | cnn.comMarriott Bonvoy Bold credit card review 2023November 4, 2023 | yahoo.comKristen Louelle Is Bold and Beautiful in These 4 Pics in Atlantic CityOctober 27, 2023 | usatoday.comWhat Top 25 upsets are coming this weekend? Bold predictions for Week 5 in college footballApril 27, 2023 | forbes.comHow Bold Leadership Can Help Or Hurt YouSee More Headlines Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BOLD CUSIPN/A CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+531.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio10.54 Quick Ratio10.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares22,250,000Free Float21,075,000Market Cap$80.99 million OptionableNo Data BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Matthew R. Patterson (Age 47)Co-Founder, Chairman & CEO Ms. Natalie C. Holles (Age 46)Pres & COO Mr. Thomas P. Soloway (Age 52)Exec. VP & CFO Dr. John T. Gray (Age 56)Sr. VP & Chief Scientific Officer Mr. Andrew H. ChangDirector of Investor RelationsKey CompetitorsAkebia TherapeuticsNASDAQ:AKBAAlimera SciencesNASDAQ:ALIMPrelude TherapeuticsNASDAQ:PRLDPrecigenNASDAQ:PGENHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInsidersRa Capital Management, L.P.Bought 312,500 shares on 4/2/2024Total: $5 M ($16.00/share)Kristina BurowBought 200,000 shares on 4/2/2024Total: $3.20 M ($16.00/share)View All Insider Transactions BOLD Stock Analysis - Frequently Asked Questions How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) released its quarterly earnings data on Monday, August, 12th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.03. When did Audentes Therapeutics IPO? Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share. When does the company's lock-up period expire? Audentes Therapeutics' lock-up period expires on Tuesday, September 24th. Audentes Therapeutics had issued 6,250,000 shares in its IPO on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV) and bluebird bio (BLUE). This page (NASDAQ:BOLD) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
